The SDT fatty rat, a model of diabetic nephropathy, to be presented at the Keystone on Diabetes
Physiogenex will be presenting its innovative SDT fatty rat model of diabetic nephropathy at the Keystone conference on Diabetes – glucose control and beyond in Santa Fe, NM, USA, January the 27th – 31st, 2020.
Liraglutide improves diabetic nephropathy in SDT fatty rats
Dr François Briand, our Director of Research and Development, will be presenting a poster about the effects of liraglutide in the SDT fatty rat model during the poster session on Tuesday January the 28th, 2020 from noon to 2:30pm.
Feel free to contact us if you wish to meet Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.